The Rheumatology Network gout clinical focus page provides information on the latest gout news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for gout drugs.
May 14, 2022
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 14, 2022.
May 11, 2022
While genetics are linked to gout diagnosis and lifestyle factors are related to risk, the association between healthy choices and risk mitigation remained unclear.
April 13, 2022
“Understanding the drivers of this increased risk in women with gout warrants further investigation in larger datasets," investigators stated.
April 05, 2022
Jeff Peterson, MD, explains the importance of the recent FDA announcement granting priority review of the Supplemental Biologics License Application for concomitant use of pegloticase injection (KRYSTEXXA) plus methotrexate for patients with uncontrolled gout.
April 02, 2022
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 2, 2022.
April 01, 2022
Supported self-management approaches have been shown to benefit patients with chronic health conditions, including gout.
March 29, 2022
“The effects of coffee consumption on SUA levels and gout risk are controversial,” investigators explained. “There have hitherto been no reports based on its effects that consider pleiotropy.”
November 23, 2021
Robert Terkeltaub, MD, explains the results from a phase 2, dose-finding study to determine the safety and efficacy of tigulixostat in patients with gout.
November 11, 2021
Jeff Peterson, MD, discusses his study determining the complete response rate of pegloticase in conjunction with methotrexate.
November 05, 2021
Kazuki Yoshida, MD, MPH, ScD, discusses his ACR presentation entitled, “Comparative Safety of Gout "Treat-to-target" and "Usual Care" Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach.”